A5000632212- Cancer Immunotherapy and Biomarkers
- Renal cell carcinoma treatment
- Prostate Cancer Treatment and Research
- Cancer Genomics and Diagnostics
- Ferroptosis and cancer prognosis
- Prostate Cancer Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- PARP inhibition in cancer therapy
- Bladder and Urothelial Cancer Treatments
- Genetic factors in colorectal cancer
- Hormonal and reproductive studies
- Palliative Care and End-of-Life Issues
- Renal and related cancers
- Pancreatic and Hepatic Oncology Research
- CAR-T cell therapy research
- Statistical Methods in Clinical Trials
- Cancer, Lipids, and Metabolism
- Radiology practices and education
- Ubiquitin and proteasome pathways
- DNA Repair Mechanisms
- Radiation Effects in Electronics
- Colorectal Cancer Screening and Detection
- Economic and Financial Impacts of Cancer
- RNA modifications and cancer
- Healthcare professionals’ stress and burnout
Duke Medical Center
2018-2025
Duke University
2017-2024
Duke Cancer Institute
2019-2024
Cancer Institute (WIA)
2022
Prostate Cancer Foundation
2021
Duke University Health System
2020
Background Low-density lipoprotein receptor-related protein 1b (encoded by LRP1B ) is a putative tumor suppressor, and preliminary evidence suggests LRP1B- mutated cancers may have improved outcomes with immune checkpoint inhibitors (ICI). Methods We conducted multicenter, retrospective pan-cancer analysis of patients alterations treated ICI at Duke University, Johns Hopkins University (JHU) Michigan (UM). The primary objective was to assess the association between overall response rate...
<h3>Background</h3> Resistance to immune checkpoint inhibitors (ICIs) has been linked local immunosuppression independent of major ICI targets (e.g., PD-1). Clinical experience with response prediction based on PD-L1 expression suggests that other factors influence sensitivity ICIs in non-small cell lung cancer (NSCLC) patients. <h3>Methods</h3> Tumor specimens from 120 NSCLC patients 10 institutions were evaluated for by immunohistochemistry, and global proliferative profile targeted...
Background Immune checkpoint inhibitors (ICIs) have expanded treatment options for metastatic renal cell carcinoma (mRCC); however, there are limited predictive biomarkers response to ICIs in this indication, with programmed death-ligand 1 (PD-L1) status demonstrating little utility mRCC. While of ICI other tumor types, the mutation burden (TMB) mRCC is unclear. Here, we assess TMB, loss antigen presentation genes and PD-L1 correlated outcomes Methods Tumor samples from 34 patients treated...
PD-L1 immunohistochemistry (IHC) has been traditionally used for predicting clinical responses to immune checkpoint inhibitors (ICIs). However, there are at least 4 different assays and antibodies IHC, each developed with a ICI. We set test if next generation RNA sequencing (RNA-seq) is robust method determine mRNA expression levels furthermore, efficacy of response ICIs as compared routinely used, standardized IHC procedures.A total 209 cancer patients treated on-label by FDA-approved ICIs,...
PURPOSE There are limited data available on the real-world patterns of molecular testing in men with advanced prostate cancer. We thus sought to evaluate next-generation sequencing (NGS) United States, focused single versus serial NGS testing, different disease states (hormone-sensitive v castration-resistant, metastatic vs nonmetastatic), tissue plasma circulating tumor DNA (ctDNA) assays, and how often actionable were found each test. METHODS The Prostate Cancer Precision Medicine...
PURPOSE Outcomes data for DNA-damaging therapeutics men with prostate cancer (PC) and non- BRCA1/2 homologous recombination repair (HRR) mutations are limited. We evaluated outcomes by HRR alteration in PC treated poly(ADP-ribose)polymerase inhibitors (PARPi) and/or platinum chemotherapy. METHODS Retrospective from the PROMISE consortium were used. Clinical differences assessed between patients BRCA1/ 2 (cohort A) those without direct BRCA complex interaction B: ATM, CDK12, CHEK1, CHEK2,...
169 Background: Combination therapies, such as androgen deprivation therapy (ADT) + receptor pathway inhibitor (ARPI) +/- docetaxel, were shown to improve overall survival (OS) in pts with mHSPC. However, some are still characterized by EP. EMETPRO study analyzed these and their response treatments administered at progression. Methods: is a multicenter, retrospective registry of EP mHSPC defined who have progression ≤ 6 months (m) under combination therapies (ADT docetaxel or ADT ARPI) 9 m...
Black men have higher incidence and mortality from prostate cancer. Whether precision oncology disparities affect with metastatic castration-resistant cancer (mCRPC) is unknown.To compare medicine data outcomes between White mCRPC.This retrospective cohort study used collected by the Prostate Cancer Precision Medicine Multi-Institutional Collaborative Effort (PROMISE) consortium, a multi-institutional registry linked clinicogenomic data, April 2020 to December 2021. Participants included...
Background Immunotherapy combinations including ipilimumab and nivolumab are now the standard of care for untreated metastatic renal cell carcinoma (mRCC). Biomarkers response lacking to predict patients who will have a favorable or unfavorable immunotherapy. This study aimed use OmniSeq transcriptome-based platform develop biomarkers Methods Two cohorts were retrospectively collected. These included an investigational cohort with mRCC treated immune checkpoint inhibitor therapy from five...
Abstract Background AR gene alterations can develop in response to pressure of testosterone suppression and androgen receptor targeting agents (ARTA). Despite this, the relevance these context ARTA treatment clinical outcomes remains unclear. Methods Patients with castration-resistant prostate cancer (CRPC) who had undergone genomic testing received were identified Prostate Cancer Precision Medicine Multi-Institutional Collaborative Effort (PROMISE) database. stratified according timing...
Biomarkers predicting immunotherapy response in metastatic renal cell cancer (mRCC) are lacking. PD-L1 immunohistochemistry is a complementary diagnostic for immune checkpoint inhibitors (ICIs) mRCC, but has shown minimal clinical utility and not used routine practice.Tumor specimens from 56 patients with mRCC who received nivolumab were evaluated PD-L1, proliferation (targeted RNA-seq), outcome.For treated as standard of care, there 2 complete responses 8 partial rate 17.9%. Dividing into...
A man in his 50s with metastatic hormone-sensitive prostate cancer, receiving androgen deprivation therapy and abiraterone acetate/prednisone, presented an uncontrollable ‘Irish brogue’ accent despite no Irish background, consistent foreign syndrome (FAS). He had neurological examination abnormalities, psychiatric history or MRI of the brain abnormalities at symptom onset. Imaging revealed progression undetectable prostate-specific antigen levels. Biopsy confirmed transformation to small...
3007 Background: Low-density lipoprotein receptor-related protein 1b (LRP1b) is a putative tumor suppressor and one of the most frequently altered genes in cancer. Our prior single-center work suggested that LRP1B alterations may enrich for responses to immune checkpoint inhibitors (ICI) solid tumors including prostate cancer; however, validation these findings needed. Methods: We conducted multicenter, retrospective analysis patients with (on tissue-based next-generation sequencing panels)...
589 Background: ICIs have revolutionized treatment for mRCC; however there are limited predictive biomarkers response to ICIs. PD-L1 status is still controversial demonstrating little utility in mRCC. TMB melanoma and non-small cell lung cancer (NSCLC), but has not been validated Here, we assess the correlations between with outcomes ICI Methods: 34 patients (pts) mRCC who had previously received therapy at Duke Cancer Institute were identified. Tumor samples retrospectively evaluated using...
We present the case of a patient with germline CHEK2- mutated metastatic castration-resistant prostate cancer (mCRPC) who responded to bipolar androgen therapy (BAT) combined pembrolizumab after progressing through multiple lines therapy. The was diagnosed in his 40s following an elevated screening prostate-specific antigen and biopsy. Over course 20 years, he progressed nearly all standard therapies including deprivation, blockade, traditional chemotherapy, targeted experimental agents. He...
Despite calls for a controlled organ donation after circulatory death (cDCD) consent process that is more rigorous, consistent, and transparent, little known about the cDCD processes utilized by U.S. hospitals. The objective of this research was to describe policies transplant hospitals, including antemortem interventions (AMI), in order inform development rigorous sound process.Cross-sectional study data hospitals were collected between July 2013 October 2014. Respondents submitted their...
e16079 Background: ICIs have revolutionized treatment for mRCC; however there are limited predictive biomarkers response to ICIs. PD-L1 status is still controversial, demonstrating little utility in mRCC. TMB melanoma and non-small cell lung cancer (NSCLC), but has not been validated Here, we assess the correlations between with outcomes ICI Methods: 34 patients (pts) mRCC who had previously received at Duke Cancer Institute were identified. Tumor samples retrospectively evaluated using a...
62 Background: Cell proliferation is an important marker of survival in many tumors, and we hypothesized that this attribute could be related to response immune checkpoint inhibitors (ICIs) RCC. Previously reported (SITC 2018) moderately proliferative lung cancer have a much higher rate than either poorly or highly tumors. Methods: 69 FFPE RCC tumor samples were evaluated by RNA-seq measure transcript levels 394 genes. was defined as the mean mRNA expression 10 genes (BUB1, CCNB2, CDK1,...
Black men have a higher prevalence of and mortality rate from prostate cancer compared with White been shown to present more aggressive later-stage disease. How treatment affects these racial disparities is still unclear. Several studies that who receive pronounced decrease in cancer-specific death; however, there remains large disparity all-cause mortality. This may be part related risk death resulting comorbidities, given the rates cardiovascular disease diabetes men, both which are...